NL300760I2 - Edoxaban, a salt thereof, a solvate thereof or an N-oxide thereof, in particular edoxaban tosylate - Google Patents

Edoxaban, a salt thereof, a solvate thereof or an N-oxide thereof, in particular edoxaban tosylate

Info

Publication number
NL300760I2
NL300760I2 NL300760C NL300760C NL300760I2 NL 300760 I2 NL300760 I2 NL 300760I2 NL 300760 C NL300760 C NL 300760C NL 300760 C NL300760 C NL 300760C NL 300760 I2 NL300760 I2 NL 300760I2
Authority
NL
Netherlands
Prior art keywords
edoxaban
solvate
salt
oxide
tosylate
Prior art date
Application number
NL300760C
Other languages
English (en)
Dutch (nl)
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27482359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300760(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/JP2002/006141 external-priority patent/WO2003000680A1/ja
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of NL300760I2 publication Critical patent/NL300760I2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NL300760C 2001-06-20 2015-09-29 Edoxaban, a salt thereof, a solvate thereof or an N-oxide thereof, in particular edoxaban tosylate NL300760I2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2001187105 2001-06-20
JP2001243046 2001-08-09
JP2001311808 2001-10-09
JP2001398708 2001-12-28
PCT/JP2002/002683 WO2003000657A1 (fr) 2001-06-20 2002-03-20 Derives de diamine
PCT/JP2002/006141 WO2003000680A1 (fr) 2001-06-20 2002-06-20 Derives de diamine

Publications (1)

Publication Number Publication Date
NL300760I2 true NL300760I2 (en) 2017-07-20

Family

ID=27482359

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300760C NL300760I2 (en) 2001-06-20 2015-09-29 Edoxaban, a salt thereof, a solvate thereof or an N-oxide thereof, in particular edoxaban tosylate

Country Status (12)

Country Link
US (7) US7365205B2 (instruction)
EP (1) EP2343290A1 (instruction)
AR (1) AR036102A1 (instruction)
BE (1) BE2015C046I2 (instruction)
CY (2) CY1113054T1 (instruction)
FR (1) FR15C0068I2 (instruction)
MY (1) MY153231A (instruction)
NL (1) NL300760I2 (instruction)
PT (1) PT1405852E (instruction)
TW (1) TWI298066B (instruction)
WO (1) WO2003000657A1 (instruction)
ZA (1) ZA200309866B (instruction)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI288745B (en) * 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
EP1405852B9 (en) * 2001-06-20 2013-03-27 Daiichi Sankyo Company, Limited Diamine derivatives
US7365205B2 (en) * 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
IL160204A0 (en) * 2001-08-09 2004-07-25 Daiichi Seiyaku Co Diamine derivatives
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
AU2003292828B9 (en) * 2002-12-25 2009-10-01 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
US7115646B2 (en) * 2003-10-08 2006-10-03 Bristol Myers Squibb, Co. Cyclic diamines and derivatives as factor Xa inhibitors
US7547786B2 (en) * 2003-11-12 2009-06-16 Daiichi Sankyo Company, Limited Process for producing thiazole derivative
US7488747B2 (en) * 2003-12-29 2009-02-10 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
EP1773780A4 (en) * 2004-06-24 2008-01-09 Incyte Corp AMIDO COMPOUNDS AND USES THEREOF AS PHARMACEUTICAL PRODUCTS
BRPI0512410A (pt) * 2004-06-24 2008-03-04 Incyte Corp compostos de amido e seu uso como produtos farmacêuticos
JP2008504280A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション ２−メチルプロパンアミドおよびその医薬としての使用
WO2006012226A2 (en) 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
EP1773773A4 (en) * 2004-06-24 2009-07-29 Incyte Corp AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS
MXPA06014573A (es) * 2004-06-24 2007-03-12 Incyte Corp Compuestos amido y su uso como farmaceuticos.
US20060122197A1 (en) * 2004-08-10 2006-06-08 Wenqing Yao Amido compounds and their use as pharmaceuticals
US7499687B2 (en) * 2004-11-09 2009-03-03 Theta Microelectronics, Inc. Wireless transmitter DC offset recalibration
US8110581B2 (en) * 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
US20060122210A1 (en) * 2004-11-18 2006-06-08 Wenqing Yao Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same
CN101115743B (zh) * 2005-02-18 2011-04-13 阿皮德公开股份有限公司 用于制备2h-色烯的新方法
US8088796B2 (en) 2005-03-31 2012-01-03 Daiichi Sankyo Company, Limited Triamine derivative
US20080293726A1 (en) 2005-07-06 2008-11-27 Sepracor Inc. Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
JPWO2007032371A1 (ja) 2005-09-14 2009-03-19 大日本住友製薬株式会社 摂食調節剤としてのオキシインドール誘導体
CA2621640C (en) * 2005-09-16 2013-10-29 Daiichi Sankyo Company, Limited Optically active diamine derivative and process for producing the same
CA2621255A1 (en) * 2005-09-21 2007-04-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
CA2630492C (en) * 2005-12-05 2015-04-14 Incyte Corporation Spiro-lactam compounds
RU2430913C2 (ru) * 2006-01-06 2011-10-10 Сепракор Инк. Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина
CN104276955A (zh) * 2006-01-06 2015-01-14 赛诺维信制药公司 基于四氢萘酮的单胺再摄取抑制剂
US7998959B2 (en) * 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
JP2009525333A (ja) * 2006-01-31 2009-07-09 インサイト・コーポレイション アミド化合物およびその医薬としての使用
TW200808807A (en) * 2006-03-02 2008-02-16 Incyte Corp Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007103719A2 (en) * 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
PT2816024T (pt) 2006-03-31 2017-10-20 Sunovion Pharmaceuticals Inc Aminas quirais
US20070293529A1 (en) * 2006-05-01 2007-12-20 Yun-Long Li Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
CA2652375A1 (en) * 2006-05-17 2007-11-29 Incyte Corporation Heterocyclic inhibitors of 11-.beta. hydroxyl steroid dehydrogenase type i and methods of using the same
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
WO2008026563A1 (fr) 2006-08-30 2008-03-06 Shionogi & Co., Ltd. Dérivé d'hydrazine amide
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
WO2008089453A2 (en) * 2007-01-18 2008-07-24 Sepracor Inc. Inhibitors of d-amino acid oxidase
EP2140867B2 (en) * 2007-03-29 2023-08-16 Daiichi Sankyo Company, Limited Pharmaceutical composition
NZ580429A (en) 2007-05-31 2012-04-27 Sepracor Inc Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
GB0721333D0 (en) * 2007-10-31 2007-12-12 Motac Neuroscience Ltd Medicaments
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010053583A2 (en) * 2008-11-10 2010-05-14 Dana Farber Cancer Institute Small molecule cd4 mimetics and uses thereof
WO2010067824A1 (ja) 2008-12-12 2010-06-17 第一三共株式会社 光学活性カルボン酸の製造方法
JP5305421B2 (ja) 2008-12-17 2013-10-02 第一三共株式会社 ジアミン誘導体の製造方法
JPWO2010082531A1 (ja) * 2009-01-13 2012-07-05 第一三共株式会社 活性化血液凝固因子阻害剤
JP5666424B2 (ja) * 2009-03-10 2015-02-12 第一三共株式会社 ジアミン誘導体の製造方法
EP2407450B1 (en) 2009-03-13 2015-04-22 Daiichi Sankyo Company, Limited Method for producing optically active diamine derivative
WO2010131663A1 (ja) * 2009-05-15 2010-11-18 第一三共株式会社 オキサミド誘導体
EP2444087B1 (en) 2009-06-18 2016-09-07 Daiichi Sankyo Company, Limited Pharmaceutical composition having improved solubility
FR2948372B1 (fr) 2009-07-21 2011-07-22 Servier Lab Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2011102505A1 (ja) 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
ES2600894T3 (es) 2010-02-22 2017-02-13 Daiichi Sankyo Company, Limited Preparación sólida de liberación sostenida para uso oral
WO2011102504A1 (ja) 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
WO2011115067A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 抗凝固剤の溶出改善方法
CN102791719B (zh) 2010-03-19 2015-07-29 第一三共株式会社 二胺衍生物的晶体及其制备方法
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
BR112013000085B1 (pt) 2010-07-02 2022-04-19 Daiichi Sankyo Company, Limited Processos para a preparação de sal de derivado de diamina opticamente ativo
HUP1000598A2 (en) 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
CA2824885A1 (en) 2011-01-19 2012-07-26 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
US9977846B2 (en) 2011-07-08 2018-05-22 Daiichi Sankyo Company, Limited Product quality control method
JPWO2013022059A1 (ja) 2011-08-10 2015-03-05 第一三共株式会社 ジアミン誘導体含有医薬組成物
US20130158069A1 (en) 2011-12-14 2013-06-20 Daiichi Sankyo Company, Limited Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment
CN102659757B (zh) * 2012-04-24 2013-11-06 南京药石药物研发有限公司 一种合成5-氯-3-噻吩甲醛的中间体及其制备方法
EP2893928B1 (en) 2012-09-03 2018-10-24 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
EA028093B1 (ru) 2012-09-07 2017-10-31 Новартис Аг Индолкарбоксамидные производные и их применение
WO2014081047A1 (en) 2012-11-23 2014-05-30 Daiichi Sankyo Company,Limited Process for the preparation of (1s,4s,5s)-4-bromo-6-oxabicyclo[3.2.1] octan-7-one
BR112015022191A8 (pt) 2013-03-15 2018-01-23 Celgene Avilomics Res Inc compostos heteroarila e usos dos mesmos
EP3943087A1 (en) 2013-03-15 2022-01-26 Celgene CAR LLC Heteroaryl compounds and uses thereof
TWI602803B (zh) 2013-03-29 2017-10-21 第一三共股份有限公司 光學活性二胺衍生物之製造方法
CN104936961B (zh) 2013-03-29 2016-10-26 第一三共株式会社 (1s,4s,5s)-4-溴-6-氧杂二环[3.2.1]辛-7-酮的制备方法
EP3038620A1 (en) 2013-08-29 2016-07-06 Daiichi Sankyo Co., Ltd. Agent for the treatment and prevention of cancer
JP2017509622A (ja) 2014-03-31 2017-04-06 第一三共株式会社 抗凝固薬として使用されるビタミンＫ拮抗薬に感受性を有する患者における、出血事象及び関連障害を治療及び予防するための第Ｘａ因子阻害薬の使用
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
WO2016025681A1 (en) 2014-08-13 2016-02-18 The Trustees Of The University Of Pennsylvania Inhibitors of hiv-1 entry and methods of use thereof
CN104529729B (zh) * 2014-12-31 2016-03-30 浙江永太科技股份有限公司 一种2-氟-3-氯苯甲醛的制备方法
TWI571460B (zh) 2016-03-14 2017-02-21 中化合成生技股份有限公司 二胺衍生物之製造方法
JP6831447B2 (ja) 2016-07-13 2021-02-17 マイラン ラボラトリーズ リミテッドＭｙｌａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ アミン保護（１ｓ，２ｒ，４ｓ）−１，２ーアミノ−ｎ，ｎ−ジメチルシクロヘキサン−４−カルボキサミドの塩
WO2018069769A1 (en) 2016-10-13 2018-04-19 Daiichi Sankyo Company, Limited Pharmaceutical composition for inhibiting neointima formation of blood vessel
US10301322B2 (en) 2016-12-27 2019-05-28 Apotex Inc. Processes for the preparation of edoxaban and intermediates thereof
MX2019010717A (es) * 2017-03-10 2019-12-05 Univ Rutgers Derivados de indol como inhibidores de bomba de eflujo.
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors
TWI826474B (zh) 2018-06-27 2023-12-21 日商第一三共股份有限公司 包含二胺衍生物之顆粒劑、以及其用途及製造方法
CN112512591B (zh) 2018-09-26 2024-08-16 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
JP7408646B2 (ja) 2018-09-30 2024-01-05 ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド 抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途
CN109942600B (zh) * 2019-04-15 2021-08-20 内蒙古京东药业有限公司 一种依度沙班的制备方法
EP3993792A4 (en) * 2019-07-04 2023-07-26 Glenmark Life Sciences Limited Process for preparation of edoxaban
JP2022540114A (ja) 2019-07-10 2022-09-14 バイエル・アクチエンゲゼルシヤフト ２－（フェニルイミノ）－１，３－チアゾリジン－４－オン類の調製方法
KR102333564B1 (ko) 2019-11-28 2021-12-01 동방에프티엘(주) 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로
JP7720305B2 (ja) 2019-12-12 2025-08-07 江蘇恒瑞医薬股▲ふん▼有限公司 抗クローディン抗体薬物複合体及びその医薬用途
WO2021147993A1 (zh) 2020-01-22 2021-07-29 江苏恒瑞医药股份有限公司 抗trop-2抗体-依喜替康类似物偶联物及其医药用途
WO2021190602A1 (zh) 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
BR112022019073A2 (pt) 2020-03-25 2022-11-08 Jiangsu Hengrui Pharmaceuticals Co Ltd Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma
US20230140397A1 (en) 2020-03-25 2023-05-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-psma antibody-exatecan analogue conjugate and medical use thereof
KR20230022211A (ko) 2020-06-08 2023-02-14 바이리-바이오 (청두) 파마슈티칼 컴퍼니, 리미티드 고안정성 친수성 연결 단위를 갖는 캄프토테신 약물 및 이의 접합체
KR20220087933A (ko) 2020-12-18 2022-06-27 엠에프씨 주식회사 디아민 유도체의 제조방법
WO2022129535A1 (en) 2020-12-18 2022-06-23 Krka, D.D., Novo Mesto Edoxaban formulation containing no sugar alcohols
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
GB202107722D0 (en) 2021-05-28 2021-07-14 Lunac Therapeutics Ltd Factor XIIA Inhibitors
AU2022386505A1 (en) 2021-11-15 2024-05-23 Systimmune, Inc. Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
CN116178251A (zh) * 2021-11-26 2023-05-30 上海汇伦医药股份有限公司 一种依度沙班中间体的制备方法
AU2022402061A1 (en) 2021-12-03 2024-07-11 Systimmune, Inc. Anti-human trop2 antibody-camptothecin drug conjugate and medical use thereof
CN114456194B (zh) * 2021-12-14 2023-07-07 浙江九洲药业股份有限公司 甲苯磺酸艾多沙班的中间体及其制备方法
CN115583900A (zh) * 2022-04-29 2023-01-10 张邦成都生物医药科技有限公司 一种高纯度依度沙班中间体的制备方法
WO2023223346A1 (en) 2022-05-16 2023-11-23 Mylan Laboratories Limited An improved process for the preparation of edoxaban intermediate
CN117752813A (zh) 2022-09-26 2024-03-26 成都百利多特生物药业有限责任公司 抗cd33抗体和抗cd33抗体-药物偶联物及其用途
CN115724792A (zh) 2022-11-24 2023-03-03 上海柏狮生物科技有限公司 一种依度沙班关键中间体及其合成方法
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354120A (en) * 1964-02-26 1967-11-21 Monsanto Co Polyamides prepared from 5, 5'-diaminoindigo
WO1986007257A2 (en) * 1985-06-07 1986-12-18 The Upjohn Company Antiarrhythmic use for aminocycloalkylamides
WO1992004017A1 (en) * 1990-09-10 1992-03-19 The Upjohn Company Cis-n-(2-aminocyclohexyl)benzamide and their enantiomers as anticonvulsants
IL100576A (en) 1991-01-18 1995-11-27 Eli Lilley And Company Cephalosporin antibiotics
AU2913292A (en) 1991-11-14 1993-06-15 Bernard Derek Frutin A pressurised container
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
JPH09503994A (ja) 1993-03-03 1997-04-22 イーライ・リリー・アンド・カンパニー バラノイド
ATE166047T1 (de) 1993-03-17 1998-05-15 Meiji Seika Co Neue verbindungen mit blutplättchenaggregationshemmender aktivität
KR970001164B1 (ko) 1993-06-09 1997-01-29 한국과학기술연구원 세팔로스포린계 항생제 및 그의 제조방법
DE69426602T2 (de) 1993-10-19 2001-08-30 Sumitomo Pharmaceuticals Co., Ltd. 2,3-diaminopropionsäurederivate
TW270114B (instruction) 1993-10-22 1996-02-11 Hoffmann La Roche
US5525042A (en) 1993-11-08 1996-06-11 Clearline Systems, Inc. Liquid pump with compressed gas motive fluid
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
AU6856094A (en) 1994-06-01 1995-12-21 Yamanouchi Pharmaceutical Co., Ltd. Oxadiazole derivative and medicinal composition thereof
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US5719144A (en) 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
AU5432696A (en) 1995-04-07 1996-10-23 Pharmacopeia, Inc. Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase
ZA963391B (en) 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
US5726126A (en) 1995-06-02 1998-03-10 American Cyanamid Company 1-(3-heterocyclyphenyl)-S-triazine-2,6,6-oxo or thiotrione herbicidal agents
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
DE19536783A1 (de) * 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle Nicotinamid-Chelatbildner vom Typ N¶2¶S¶2¶ für radioaktive Isotope
US5852045A (en) 1995-10-19 1998-12-22 Merck & Co., Inc. Fibrinogen receptor antagonists
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
GB9602294D0 (en) 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
WO1997038984A1 (en) 1996-04-17 1997-10-23 Du Pont Pharmaceuticals Company N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
US5668159A (en) 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists
TR199900303T2 (xx) 1996-08-14 1999-06-21 Zeneca Limited �kame edilmi� pirimidin t�revleri ve bunlar�n farmas�tik kullan�m�.
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
US6440972B1 (en) 1997-02-13 2002-08-27 Zeneca Limited Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
IT1291823B1 (it) 1997-04-08 1999-01-21 Menarini Ricerche Spa Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche
DE69835430T2 (de) 1997-05-30 2007-03-08 Takeda Pharmaceutical Co. Ltd. Sulfonamidderivate, ihre herstellung und verwendung
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
CA2295153A1 (en) 1997-06-26 1999-01-07 Gerald Floyd Smith Antithrombotic agents
US6313122B1 (en) 1997-06-26 2001-11-06 Eli Lilly And Company Antithrombotic agents
US6417200B1 (en) 1997-06-26 2002-07-09 Eli Lilly And Company Antithrombotic agents
GB9715895D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
EP1031563B1 (en) 1997-09-30 2005-12-28 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
US6130349A (en) * 1997-12-19 2000-10-10 The Board Of Trustees Of The Leland Stanford Junior University Catalytic compositions and methods for asymmetric allylic alkylation
EP0937723A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
DE19814801A1 (de) * 1998-04-02 1999-10-07 Basf Ag Verfahren zur Herstellung von 1,3,4-trisubstituierten 1,2,4-Triazoliumsalzen
GB9807104D0 (en) 1998-04-02 1998-06-03 Chirotech Technology Ltd The preparation of phosphine ligands
ATE432923T1 (de) 1998-04-21 2009-06-15 Bristol Myers Squibb Pharma Co 5-aminoindenoä1,2-cüpyrazol-4-one als antitumor- und wachstumshemmende mittel
US6753331B1 (en) 1998-05-02 2004-06-22 Astrazeneca Ab Heterocyclic derivatives which inhibit factor Xa
GB9809350D0 (en) 1998-05-02 1998-07-01 Zeneca Ltd Novel salt
GB9809349D0 (en) 1998-05-02 1998-07-01 Zeneca Ltd Heterocyclic derivatives
WO2000000498A1 (en) 1998-06-30 2000-01-06 Chirotech Technology Limited The preparation of arylphosphines
JP2000086659A (ja) 1998-07-14 2000-03-28 Takeda Chem Ind Ltd オクタヒドロピリド［１，２―ａ］ピラジン誘導体
TW434207B (en) 1998-07-24 2001-05-16 Everlight Chem Ind Corp Chiral ligand and method for preparing cyanohydrins from aldehydes
US6303625B1 (en) 1998-07-27 2001-10-16 Ortho-Mcneil Pharmaceutical, Inc. Triazolopyridines for the treatment of thrombosis disorders
AU5196399A (en) * 1998-08-11 2000-03-06 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
WO2000039118A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Aromatic amides
ES2263294T3 (es) 1998-12-23 2006-12-01 Eli Lilly And Company Amidas antitromboticas.
CA2358095A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Heteroroaromatic amides as inhibitor of factor xa
CA2356214A1 (en) 1998-12-24 2000-07-06 Eli Lilly And Company Heterocyclic amides as inhibitors of factor xa
GB9902989D0 (en) 1999-02-11 1999-03-31 Zeneca Ltd Heterocyclic derivatives
AU2241400A (en) * 1999-04-06 2000-10-12 Yamanouchi Pharmaceutical Co., Ltd. Novel thiazolobenzoimidazole derivative
JP4390024B2 (ja) 1999-04-23 2009-12-24 アステラス製薬株式会社 新規なジアゼパン誘導体又はその塩
GB9909592D0 (en) 1999-04-26 1999-06-23 Chirotech Technology Ltd Process for the preparation of calanolide precursors
AU5283600A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
DE60022508T2 (de) 1999-06-14 2006-06-08 Eli Lilly And Co., Indianapolis Inhibitoren von serin proteasen
JP2003502296A (ja) 1999-06-15 2003-01-21 ロディア・シミ スルホニルアミド及びカルボキサミド並びに不斉触媒作用におけるそれらの使用
GB9914342D0 (en) 1999-06-19 1999-08-18 Zeneca Ltd Compound
JP2001011071A (ja) 1999-06-25 2001-01-16 Mochida Pharmaceut Co Ltd アミノアルキルスルホンアミド誘導体
US6492408B1 (en) 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
GB9917344D0 (en) 1999-07-24 1999-09-22 Zeneca Ltd Novel salt
DK1212300T3 (da) 1999-09-13 2004-03-15 Dimensional Pharm Inc Azacyclololalkanonserinproteaseinhibitorer
KR20020047175A (ko) 1999-09-17 2002-06-21 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자의 억제제
HUP0203954A2 (hu) 1999-09-17 2003-03-28 Millennium Pharmaceuticals, Inc. Xa faktor inhibitorok
AU1770001A (en) 1999-11-24 2001-06-04 Cor Therapeutics, Inc. Beta-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factorxa
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
TWI288745B (en) * 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
AU2001275857A1 (en) 2000-06-29 2002-01-14 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
AU2002214626A1 (en) 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Quaternary amines and related inhibitors of factor xa
JP2004509958A (ja) 2000-09-29 2004-04-02 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子のインヒビターとしてのピペラジン−２−オンアミド
AU2001294824A1 (en) 2000-09-29 2002-04-08 Millennium Pharmaceuticals, Inc. Piperazine based inhibitors of factor xa
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
AU2406402A (en) 2000-11-22 2002-06-03 Yamanouchi Pharma Co Ltd Substituted benzene derivatives or salts thereof
CA2432369A1 (en) 2000-12-20 2002-08-08 Bristol-Myers Squibb Pharma Company Cyclic derivatives as modulators of chemokine receptor activity
WO2002079145A1 (en) 2001-03-30 2002-10-10 Millennium Pharmaceuticals, Inc. BENZAMIDE INHIBITORS OF FACTOR Xa
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
EP1405852B9 (en) 2001-06-20 2013-03-27 Daiichi Sankyo Company, Limited Diamine derivatives
IL160204A0 (en) 2001-08-09 2004-07-25 Daiichi Seiyaku Co Diamine derivatives
BRPI0212726B8 (pt) 2001-09-21 2021-05-25 Bristol Myers Squibb Co compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
EP1505966A4 (en) 2002-05-10 2006-08-30 Bristol Myers Squibb Co 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA HEMMER
JP4601053B2 (ja) * 2002-12-24 2010-12-22 第一三共株式会社 新規なエチレンジアミン誘導体
AU2003292828B9 (en) * 2002-12-25 2009-10-01 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives

Also Published As

Publication number Publication date
US20100093785A1 (en) 2010-04-15
US20110077266A1 (en) 2011-03-31
FR15C0068I2 (fr) 2016-04-22
US20110312990A1 (en) 2011-12-22
US7342014B2 (en) 2008-03-11
FR15C0068I1 (instruction) 2015-12-04
MY153231A (en) 2015-01-29
US20090270446A1 (en) 2009-10-29
BE2015C046I2 (instruction) 2021-07-19
HK1092461A1 (en) 2007-02-09
PT1405852E (pt) 2012-10-30
EP2343290A1 (en) 2011-07-13
CY1113054T1 (el) 2016-04-13
US7365205B2 (en) 2008-04-29
US20080015215A1 (en) 2008-01-17
TWI298066B (en) 2008-06-21
US20050020645A1 (en) 2005-01-27
US20050119486A1 (en) 2005-06-02
AR036102A1 (es) 2004-08-11
ZA200309866B (en) 2005-03-30
WO2003000657A1 (fr) 2003-01-03
CY2015034I2 (el) 2016-04-13
CY2015034I1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
NL300760I2 (en) Edoxaban, a salt thereof, a solvate thereof or an N-oxide thereof, in particular edoxaban tosylate
NO2015022I2 (no) Edoksaban, et salt derav, et solvat derav eller et N-oksid derav, spesielt edoksabantosilat
NL300996I1 (nl) Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout
NL301020I2 (nl) Avatrombopag, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder avatrombopag-maleaat
NL300913I2 (nl) Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride
FR17C1012I2 (fr) 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
DK1611131T3 (da) Pyrazolopyridin-derivater
NO20054220D0 (no) Substituerte N-arylheterocykler, fremgangsmate for fremstilling derav og deres anvendelse som legemiddel
DE602004026205D1 (de) Roboterhand
NL1031976A1 (nl) N-(pyridine-2-yl)sulfonamidederivativen.
EP1668781A4 (en) CELLULAR BOOSTER WITH SHORT RANGE
DE112004001751D2 (de) Socke
ATE394659T1 (de) Probenhomogenisator
DE112004002437D2 (de) Socke
ITMO20030289A1 (it) Apparati, metodo e articolo.
DK1667668T3 (da) Alfabeta3 og altabeta6-integrinantagonister som antifibrotiske midler
DK3184275T3 (da) Polymere artikler
NL1033403A1 (nl) Therapeutische pyrazolo[3,4-b]pyridinen en indazolen.
DE602004032218D1 (de) Kontaktpunkteinrichtung
NL300918I1 (nl) Naltrexon of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder naltrexonhydrochloride, en bupropion of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bupropionhydrochloride
SE0300228L (sv) Verktyg
NO20053805D0 (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav
ITMO20030004A0 (it) Macchina utensile.
ITMI20031132A0 (it) Attrezzo da palestra perfezionato
FI20031240L (fi) Hissin tarraajajärjestely